Efficacy and safety of P2Y12 inhibitors comparable between men and women
In a meta-analysis of 7 trials, P2Y12 inhibitors prasugrel, ticagrelor and cangrelor reduced MACE and increased major bleedings in men and women similarly.
Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized TrialsLiterature - Lau ES, Braunwald E, Murphy SA, et al. - J Am Coll Cardiol. 2017;69(12):1549-1559
Background
The efficacy and safety of P2Y12 inhibitors in women is not adequately established, due to their underrepresentation in clinical studies [1,2]. There are concerns because of gender-specific differences in the pharmacodynamics and due to the fact that women are at increased risk of bleeding after acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI) [3-6].
In this meta-analysis of 7 phase III or IV RCTs, the gender-specific efficacy and safety of P2Y12 inhibitors prasugrel, ticagrelor and cangrelor were evaluated in patients with stable and unstable coronary artery disease (CAD). For this, end points with P2Y12 inhibitors were compared with these of clopidogrel (6 studies) or placebo (1 study).
Main results
- Of 87,840 patients, 27.9% were women. Women were significantly more likely to be older and to have comorbidities including diabetes mellitus, hypertension, prior stroke or TIA, prior heart failure and lower eGFR.
- Risk of primary endpoint MACE in women corresponded to an HR of 0.86, 95% CI 0.78-0.94, P=0.002 and in men to an HR of 0.85; 95% CI 0.80-0.90, P<0.001, without heterogeneity (P interaction = 0.93).
- Similar results were observed for the composite of cardiovascular (CV) death, myocardial infarction (MI) or stroke (HR in women 0.89, 95% CI 0.81-0.97, P=0.01, HR in men 0.85, 95% CI 0.80-0.90, P<0.001, P interaction = 0.60).
- In women, risk of MI (HR 0.87, 95% CI 0.78-0.96, P=0.01), CV death (HR 0.87, 95% CI 0.76-1.01, P=0.06) and risk of stroke were reduced (HR 0.92, 95% CI 0.55-1.56, P=0.76).
- In men, risk of CV death (HR 0.85, 95% CI 0.77-0.95, P=0.002, P interaction = 0.86) and of MI were reduced (HR 0.84, 95% CI 0.76-0.91, P<0.001, P interaction = 0.65), and effect was neutral effect on risk of stroke (HR 0.99, 95% CI 0.82-1.18, P=0.87, P interaction = 0.72).
- Risk of stent thrombosis in women (HR 0.49, 95% CI 0.37-0.65, P<0.001) and in men (HR 0.59, 95% CI 0.42-0.84, P=0.003, P interaction = 0.85) was reduced.
- In both men and women, risk of TIMI (non–CABG-related) major bleeding increased (HR in women 1.28, 95% CI 0.87-1.88, P=0.21, HR in men 1.52, 95% CI 1.12-2.07, P<0.01, P interaction = 0.62).
- Risk of intracranial hemorrhage in men was increased (HR 1.47, 95% CI 1.02-2.11, P=0.04), but not in women (HR 0.96, 95% CI 0.46-1.98, P=0.91). However number of events were few and test for heterogeneity by gender was not significant (P interaction = 0.24).
- All-cause mortality was reduced in women (HR 0.89, 95% CI 0.78-1.01, P=0.07) and in men (HR 0.89, 95% CI 0.81-0.99, P=0.02, P interaction = 0.99).
Conclusion
The efficacy and safety of P2Y12 inhibitors is comparable between women and men. These findings support the use of these therapies in both genders with appropriate indications for use.
References
1. Kim ES, Carrigan TP, Menon V. Enrollment of women in National Heart, Lung, and Blood Institute-funded cardiovascular randomized controlled trials fails to meet current federal mandates for inclusion. J Am Coll Cardiol 2008;52:672–3.
2. Wang TY, Angiolillo DJ, Cushman M, et al. Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. J Am Coll Cardiol 2012;59:891–900.
3. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306–13; erratum in JAMA 2006; 295:2002.
4. Berger JS, Bhatt DL, Cannon CP, et al. The relative efficacy and safety of clopidogrel in women and men: a sex-specific collaborative meta-analysis. J Am Coll Cardiol 2009;54:1935–45.
5. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002;359:189–98; erratum in Lancet 2002;359:2120.
6. Patti G, De Caterina R, Abbate R, et al. Platelet function and long-term antiplatelet therapy in women: is there a gender-specificity? A ’state-of-the-art’ paper. Eur Heart J 2014;35:2213–23b.